Glanzmann thrombasthenia. Cooperation between sequence variants in cis during splice site selection.
Authors:
- W R BellWBW R Bell
- I McIntoshIMI McIntosh
- P F BrayPBP F Bray
Open Access
- 15 October 1996
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 98 (8) , 1745-1754
Abstract
Glanzmann thrombasthenia (GT), an autosomal recessive bleeding disorder, results from abnormalities in the platelet fibrinogen receptor, GP(IIb)-IIIa (integrin alpha(IIb)beta3). A patient with GT was identified as homozygous for a G-->A mutation 6 bp upstream of the GP(IIIa) exon 9 splice donor site. Patient platelet GP(IIIa) transcripts lacked exon 9 despite normal DNA sequence in all of the cis-acting sequences known to regulate splice site selection. In vitro analysis of transcripts generated from mini-gene constructs demonstrated that exon skipping occurred only when the G-->A mutation was cis to a polymorphism 116 bp upstream, providing precedence that two sequence variations in the same exon which do not alter consensus splice sites and do not generate missense or nonsense mutations, can affect splice site selection. The mutant transcript resulted from utilization of a cryptic splice acceptor site and returned the open reading frame. These data support the hypothesis that pre-mRNA secondary structure and allelic sequence variants can influence splicing and provide new insight into the regulated control of RNA processing. In addition, haplotype analysis suggested that the patient has two identical copies of chromosome 17. Markers studied on three other chromosomes suggested this finding was not due to consanguinity. The restricted phenotype in this patient may provide information regarding the expression of potentially imprinted genes on chromosome 17.Keywords
This publication has 73 references indexed in Scilit:
- Molecular basis for Glanzmann's thrombasthenia (GT) in a compound heterozygote with glycoprotein IIb gene: a proposal for the classification of GT based on the biosynthetic pathway of glycoprotein IIb-IIIa complex.1992
- A new variant of Glanzmann's thrombasthenia (Strasbourg I). Platelets with functionally defective glycoprotein IIb-IIIa complexes and a glycoprotein IIIa 214Arg----214Trp mutation.Journal of Clinical Investigation, 1992
- Integrins: Versatility, modulation, and signaling in cell adhesionCell, 1992
- Severe Silver‐Russell syndrome and translocation (17;20) (q25;q13)Clinical Genetics, 1992
- Mutations which alter splicing in the human hypoxanthine-guanine phosphoribosyltransferase geneNucleic Acids Research, 1992
- SPLICING OF MESSENGER RNA PRECURSORSAnnual Review of Biochemistry, 1986
- A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa.Journal of Clinical Investigation, 1983
- Inhibition of fibrinogen binding to stimulated human platelets by a monoclonal antibody.Proceedings of the National Academy of Sciences, 1983
- FIBRINOGEN-BINDING PROPERTIES OF THE HUMAN-PLATELET GLYCOPROTEIN IIB-IIIA COMPLEX - A STUDY USING CROSSED-RADIOIMMUNOELECTROPHORESIS1982
- An algorithm for the display of nucleic acid secondary structureNucleic Acids Research, 1982